I'm sure Docs are still a little hesitant but at least showing interest in prescribing it which is good news. May be his/her Doctor just wants them to ease into for self assurance of no side effects. Once the Doctor confirms there are none he will suggest him/her to continue as the label says to do.
Funny they had an opinion before it was even released. They should stick to vacuums which they still suck at!
The measures of the whole group is not showing up for some reason. Check the link out below after fixing it (it's a Yahoo thing) for the publication.
Published: 26 June 2014
100 participants completed the study and were included in data analysis. Two female patients (one in the taVNS group, one in the sham taVNS group) dropped out of the study due to stimulation-evoked dizziness. The symptoms were relieved after stopping treatment. Compared with sham taVNS, taVNS significantly reduced the two-hour glucose tolerance (F(2) = 5.79, p = 0.004). In addition, we found that taVNS significantly decreased (F(1) = 4.21, p = 0.044) systolic blood pressure over time compared with sham taVNS. Compared with the no-treatment control group, patients receiving taVNS significantly differed in measures of FPG (F(2) = 10.62, p
Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators hypothesized that decreased vagus nerve activity may be the underlying mechanism of metabolic syndrome including obesity, elevated glucose levels, and high blood pressure.
In this pilot randomized clinical trial, we compared the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) and sham taVNS on patients with IGT. 72 participants with IGT were single-blinded and were randomly allocated by computer-generated envelope to either taVNS or sham taVNS treatment groups. In addition, 30 IGT adults were recruited as a control population and not assigned treatment so as to monitor the natural fluctuation of glucose tolerance in IGT patients. All treatments were self-administered by the patients at home after training at the hospital. Patients were instructed to fill in a patient diary booklet each day to describe any side effects after each treatment. The treatment period was 12 weeks in duration. Baseline comparison between treatment and control group showed no difference in weight, BMI, or measures of systolic blood pressure, diastolic blood pressure, fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), or glycosylated hemoglobin (HbAlc).
I agree, I thought for sure as many did there would be more significant of a drop which wasn't the case. Now that the holidays are out of the picture for awhile and the TV campaign seems to be in full swing I think we will know in a few more weeks where Arena is headed. Also, institutions who are putting new money to work may be taking a closer look as well being we are coming into the winter months when more people seem to care a little more for some reason or another. Arena is at the tipping point imo and Eisai needs to make this happen now rather than later!
Agreed Doc!! Hope all is well and things can get turned around here soon. It's been a long and painful grind for many here who have been shafted by folks from all sides. GL
Another load of BS. As another poster stated Arena actually has a manufacturing facility where THEY control how many pills are manufactured. Vivus on the other hand has to guesstimate and well no need to explain the rest.
I never could understand why anyone would short a company after receiving a positive recommendation. With that said shorts know they have time on their side for a few more months and will do everything they can to make a dime or two until then. Of course there are short traders who believe the FDA will not approve the devise but that's a stretch imo. Just look at it this way. If you are long and holding through a decision by the FDA with the belief approval is around the corner as I am, then shorts might just be the best thing to happen.
You're like a tick, but as to whether or not i'm back in the answer is NO! I'm just following the obesity space like I have been for several years now. I still think there's some downside risk left being tomorrow's script numbers will probably come in very light. I could be wrong about though being the needle has moved so far down recently with Jacks boneheaded move. Scripts may actually be overlooked. I will re-think my strategy in a few more weeks when we see if the new push in TV ads does the trick. Until then i'm on the sidelines.
I'm not sure if this has been posted or not. So I thought I would share it with everyone but "Swalchie".
A study of 509 type 2 diabetes patients found that lorcaserin was more effective than diet and exercise alone in reducing A1C levels regardless of whether the patients lost weight. The patients, randomly assigned to either lorcaserin or placebo along with diet and exercise, had A1c levels between 7% and 10%, as well as similar fasting plasma glucose levels. The researchers defined responders as patients who achieved the primary endpoint of weight loss of at least 5% at 52 weeks of treatment. Presented June 24 at American Association of Nurse Practitioners meeting.
Is there really a difference? Both words mean the same thing. By the way, if your long you have been begging for more PR's so he gave you one. Hopefully the contract reps are paid based on performance, it does and should make a difference.
The neuromodulation market is led by North America, followed by Europe, and Asia-Pacific The key players in the neuromodulation market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.)
Markets and Markets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
The neuromodulation market is predicted to expand exponentially in the coming decade, driven by rapid advances in technology and clinical trials, approval of innovative devices, rise in population suffering from age-related disorders, and the presence of a large number of niche companies.
Dallas, TX -- Jul 09, 2014 / Neuromodulation is a safe treatment for people suffering from epilepsy, Parkinson’s, chronic pain, failed back surgery syndrome (FBSS/FBS), heart failure, incontinence, stroke, headache, depression, along with emerging applications for migraine, tinnitus, sleep apnea, spinal cord injury, Alzheimer’s disease, obesity, and others.
Neuromodulation is considered a promising field of the medical device industry. It originated thousands of years ago with the use of electricity from electric fish to treat pain and other conditions; this medical application gained industrial popularity in the mid-18th century. Revolution in neuromodulation technology began in 1960 with the development of the deep brain stimulation technique, soon followed by spinal cord stimulation.
The concept of neuromodulation is based on the reversible alteration of the nervous system. Being reversible in nature, this technique is safe and has varied applicability as it can be turned off any time in all types of treatments. Neuromodulation involves the use of electrodes implanted at specific places in the brain, spinal cord, and peripheral nerves. These electrodes comprise of leads that are further connected by means of an extension cable to a pulse generator and power source, which generate mild electrical pulses to modulate the specific nerves.
One more thing. We should or I would hope to see a decline in dollars spent being that we are past the cost associated with the (PMA) and wrapping up expensive clinical trials. Grant it there will continue to be trials but at what cost? I don't think you or I know that for sure.
"Operating expenses were primarily associated with the cost of supporting multiple ongoing clinical trials, including the ReCharge Study, the Company’s VBLOC ® vagal blocking therapy, Premarket Approval (PMA) application, and the continued development of VBLOC Therapy"
Your scare tactics aren't going to fly here. So tell me, are you really shorting a $1 stock?
“Based on our current capital and expense projections, we have the resources to fund operations through this pivotal regulatory milestone and to begin building our commercial infrastructure in anticipation of a positive FDA approval decision for VBLOC Therapy this year."
Okay, your point being? Like I said before, unless they are going it alone there will be NO reason to further dilute shares. Here is some DD I will share with you
"“Based on our current capital and expense projections, we have the resources to fund operations through this pivotal regulatory milestone and to begin building our commercial infrastructure in anticipation of a positive FDA approval decision for VBLOC Therapy this year."
Arena needs an activist investor to step in. If it keeps this up I wouldn't be surprised to see one.